sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks N-DESMETHYL ROSIGLITAZONE

N-DESMETHYL ROSIGLITAZONE

CAS No.:
257892-31-2
Catalog Number:
AG00C367
Molecular Formula:
C17H17N3O3S
Molecular Weight:
343.4002
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
≥98%
1 week
United States
$172
- +
5mg
≥98%
1 week
United States
$507
- +
10mg
≥98%
1 week
United States
$807
- +
Product Description
Catalog Number:
AG00C367
Chemical Name:
N-DESMETHYL ROSIGLITAZONE
CAS Number:
257892-31-2
Molecular Formula:
C17H17N3O3S
Molecular Weight:
343.4002
MDL Number:
MFCD08063704
IUPAC Name:
5-[[4-[2-(pyridin-2-ylamino)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
InChI:
InChI=1S/C17H17N3O3S/c21-16-14(24-17(22)20-16)11-12-4-6-13(7-5-12)23-10-9-19-15-3-1-2-8-18-15/h1-8,14H,9-11H2,(H,18,19)(H,20,21,22)
InChI Key:
ZJQTVMXUIGXRMR-UHFFFAOYSA-N
SMILES:
O=C1NC(=O)C(S1)Cc1ccc(cc1)OCCNc1ccccn1
Properties
Complexity:
441  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
343.099g/mol
Formal Charge:
0
Heavy Atom Count:
24  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
343.401g/mol
Monoisotopic Mass:
343.099g/mol
Rotatable Bond Count:
7  
Topological Polar Surface Area:
106A^2
Undefined Atom Stereocenter Count:
1  
Undefined Bond Stereocenter Count:
0
XLogP3:
3  
Literature
Title Journal
The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate. British journal of clinical pharmacology 20120801
Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats. Xenobiotica; the fate of foreign compounds in biological systems 20060901
Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. Journal of clinical pharmacology 20050801
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 20031001
Properties